Log in

AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

$14.79
+0.08 (+0.54 %)
(As of 10/18/2019 07:48 AM ET)
Today's Range
$14.74
Now: $14.79
$14.92
50-Day Range
$14.46
MA: $17.28
$19.31
52-Week Range
$13.72
Now: $14.79
$25.48
Volume104,471 shs
Average Volume341,599 shs
Market Capitalization$556.40 million
P/E Ratio17.82
Dividend YieldN/A
Beta0.71
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$359.48 million
Cash Flow$1.52 per share
Book Value$16.32 per share

Profitability

Net Income$61.34 million

Miscellaneous

Employees1,050
Market Cap$556.40 million
Next Earnings Date1/3/2020 (Estimated)
OptionableOptionable

Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.


AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings data on Thursday, October, 3rd. The medical instruments supplier reported $0.08 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.04. The medical instruments supplier earned $66 million during the quarter, compared to analyst estimates of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The company's revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter last year, the business posted $0.16 EPS. View AngioDynamics' Earnings History.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share (EPS) guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

What price target have analysts set for ANGO?

2 Wall Street analysts have issued 1-year price targets for AngioDynamics' shares. Their forecasts range from $21.00 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $22.00 in the next year. This suggests a possible upside of 48.7% from the stock's current price. View Analyst Price Targets for AngioDynamics.

What is the consensus analysts' recommendation for AngioDynamics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Has AngioDynamics been receiving favorable news coverage?

News articles about ANGO stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AngioDynamics.

Are investors shorting AngioDynamics?

AngioDynamics saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,130,000 shares, a decrease of 17.5% from the August 30th total of 1,370,000 shares. Based on an average daily volume of 235,900 shares, the days-to-cover ratio is currently 4.8 days. Currently, 3.1% of the company's stock are short sold. View AngioDynamics' Current Options Chain.

Who are some of AngioDynamics' key competitors?

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), General Electric (GE), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the folowing people:
  • Mr. James C. Clemmer, CEO, Pres & Director (Age 55)
  • Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)
  • Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)
  • Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)
  • Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47)

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (1.80%), Envestnet Asset Management Inc. (0.17%), Assenagon Asset Management S.A. (0.15%), State of Alaska Department of Revenue (0.08%), Campbell & CO Investment Adviser LLC (0.05%) and Meeder Asset Management Inc. (0.05%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meeder Asset Management Inc., State of Alaska Department of Revenue, Pacer Advisors Inc., Nisa Investment Advisors LLC, Campbell & CO Investment Adviser LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for AngioDynamics.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $14.79.

How big of a company is AngioDynamics?

AngioDynamics has a market capitalization of $556.40 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

What is AngioDynamics' official website?

The official website for AngioDynamics is http://www.angiodynamics.com/.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]


MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  382 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel